Teva Pharmaceutical Industries Limited (TEVA)

Teva Pharmaceutical Industries Limited (TEVA) is a healthcare company (drug manufacturers - specialty & generic) based in Israel. The share price is $42.03, down 1.27% on the day, which values the company at $49.04B. Price as of 17 Nov 2026, 17:38 UTC, from Yahoo Finance.

Key facts

Share price
$42.03−1.27% today
Market value
$49.04B
P/E ratio
97.7×last 12 months
Forward P/E
13.5×
Funk Score
43/100
Against its own history
Well above its usual priceusual price $12.56
200-week average
$19.52115% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Teva Pharmaceutical Industries Limited in more detail

TEVA trades at 97.7× its last twelve months' earnings, 13.5× next year's expected earnings, 2.8× sales. Measured against its own history, the price is 235% above what its usual multiples would imply ($12.56) — well above its usual price. It sits 115% above its 200-week average of $19.52.

Over the last five fiscal years Teva Pharmaceutical Industries Limited has compounded revenue 0.7% a year, free cash flow 12.5% a year. Its Funk Score is 43 out of 100 (financial strength 3.4, profitability 6.2, growth 4.3, value 3.2, each out of 10).

In its favour: Strong Piotroski score; Operating margin is expanding. Worth checking: Altman Z in the distress zone; Share count keeps rising.

7 of the superinvestors tracked here hold TEVA, including Harry Burn (4.5% of the portfolio), Larry Robbins (3.4% of the portfolio), David Einhorn (2.5% of the portfolio).

Superinvestors holding TEVA

7 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:TEVA vs A (Teva Pharmaceutical Industries Limited vs Agilent Technologies)TEVA vs HUM (Teva Pharmaceutical Industries Limited vs Humana)TEVA vs ONC (Teva Pharmaceutical Industries Limited vs BeOne Medicines)TEVA vs MDLN (Teva Pharmaceutical Industries Limited vs Medline)TEVA vs WAT (Teva Pharmaceutical Industries Limited vs Waters)

All health care companies by market valueLargest companies in IsraelAll stocks A–Z

Teva Pharmaceutical Industries Limited (TEVA): questions and answers

What is TEVA's P/E ratio?

Teva Pharmaceutical Industries Limited trades at 97.7× its last twelve months' earnings and 13.5× next year's expected earnings. At its fiscal year-ends over the past 11 years the P/E ranged from 13.1× to 56.8×, with a median of 21.1×.

What is TEVA's PEG ratio?

Teva Pharmaceutical Industries Limited's PEG ratio is 0.71 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Teva Pharmaceutical Industries Limited's market cap?

Teva Pharmaceutical Industries Limited is valued at $49.04B at a share price of $42.03.

Is TEVA overvalued or undervalued?

Against its own history, TEVA is well above its usual price: the price is 235% above the $12.56 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is TEVA above its 200-week moving average?

Yes. TEVA is 115.3% above its 200-week average of $19.52. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Teva Pharmaceutical Industries Limited growing?

Over the last five fiscal years Teva Pharmaceutical Industries Limited's revenue grew 0.7% a year; over ten years revenue grew -1.3% a year.

Cite this page

Funkfolio, “Teva Pharmaceutical Industries Limited (TEVA) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/TEVA

Underlying data: Yahoo Finance; company filings with the SEC.